Accuray Announces Rapid Clinical Adoption of TomoDirect(TM) Treatment Delivery Mode

SUNNYVALE, Calif., Oct. 26, 2011 /PRNewswire via COMTEX/ --

Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today significant momentum in global adoption of its TomoDirect treatment modality. More than 100 systems are now in use at leading cancer centers throughout the world, offering patients the option of treatment with image-guided, intensity-modulated radiation therapy (IG-IMRT) for routine radiation therapy indications.

First delivered to the market in 2010, TomoDirect is a standard feature on the TomoHD(TM) Treatment System. It is optimized for delivering radiation at fixed angles, making it highly efficient for whole breast radiotherapy and other cases where select beam angles are most appropriate. Global adoption continues, with over 75 percent of system orders in the past six months including TomoDirect.

The Institute for Image-Guided RadioTherapy (IIGRT) in Westchester, Rye, New York is one of the first centers in the world to offer TomoDirect treatments. IIGRT performs both whole breast and accelerated partial breast irradiation (APBI) with TomoDirect.

"IIGRT has been using the TomoTherapy System since 2007 and we have significantly increased our treatment capacity with the addition of TomoDirect last year, because we can now offer TomoTherapy to an expanded patient population," said Dr. Daniel Fass, director of IIGRT. "TomoDirect offers a highly accurate and convenient method for delivering APBI. This allows us to offer many breast cancer patients a shorter course of high quality radiation therapy treatments. We also use TomoDirect for conventional breast treatments when it offers a dosimetric advantage over Helical TomoTherapy."

Accuray's TomoHD Treatment System is a comprehensive solution that efficiently handles clinical indications of any complexity. The system offers both TomoDirect and TomoHelical treatment modes to allow clinicians to deliver treatment options for a range of clinical indications and enables daily 3D CT imaging of every patient, prior to each treatment, to maximize treatment accuracy. The TomoDirect modality is efficient in applying multiple targeted radiation beams to the tumor for more routine cases while TomoHelical is designed for more complex cases, delivering radiation throughout multiple 360 degree gantry rotations.

"The combination of TomoDirect and TomoHelical on the TomoHD System creates a single efficient and clinically flexible radiation therapy treatment solution," said Omar Dawood M.D., M.P.H., senior vice president, Global Medical Affairs, Accuray Incorporated. "By expanding the reach of TomoTherapy technology, the addition of TomoDirect allows physicians to offer the highest quality treatments tailored for each individual patient's specific clinical needs. The increase in global adoption of TomoDirect is a testament to the clinical benefits of the technology."

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company's technologies and more than 582 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical applications, clinical experience, clinical benefits and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2011 fiscal year filed on September 19, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated